A method for treating breast cancer in a subject having a breast cancer over-expressing the &ldquoSHP2 signature&rdquo genes, as compared to normal breast tissue samples, which method comprises the step of administering to said subject a therapeutically effective amount of a modulator of the protein tyrosine phosphatase, non-receptor type 11 (PTPN11) gene or of its gene product (Shp2).